Vertex Pharmaceuticals

AI stocks declined globally, dragging down major indices like the S&P 500, Nasdaq, and Dow Jones. Samsung Electronics, Micron Technology, and Intel saw significant drops, while rising oil prices and geopolitical tensions in the Strait of Hormuz added pressure to markets.

AI stocks fell sharply, dragging down global markets including the S&P 500, Nasdaq, and Dow Jones. Samsung Electronics dropped 6.9% in South Korea despite strong quarterly results, while Micron and Nvidia also declined. Concerns about overvaluation and AI's profitability, along with rising oil prices and corporate news, weighed on investor sentiment.

AI stocks declined sharply on Wall Street despite Samsung Electronics' strong Q2 profit forecast, as investors questioned the sustainability of AI sector valuations. The Nasdaq fell 1.2% and the S&P 500 dropped 0.6%, led by heavy losses in AI-related companies like Micron Technology and Nvidia. Rising oil prices and geopolitical tensions in the Strait of Hormuz further pressured markets.

Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for $10 billion, gaining access to Palsonify, a drug for acromegaly, and other drug candidates. The deal marks Vertex's largest acquisition as it expands beyond its cystic fibrosis portfolio.

Vertex Pharmaceuticals is acquiring Crinetics to expand into rare hormonal diseases. The deal provides access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia.

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, gaining access to its drug Palsonify for acromegaly and other drug candidates. The acquisition, valued at $85 per share, caused Crinetics' shares to rise 101% in after-hours trading.